Georgia's Online Cancer Information Center

Find A Clinical Trial

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status
Active
Cancer Type
Bladder Cancer
Brain & Spinal Cord Tumor
Breast Cancer
Cervical Cancer
Colon/Rectal Cancer
Esophogeal Cancer
Head and Neck Cancer
Kidney Cancer
Liver Cancer / Hepatoblastoma
Lung Cancer
Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Plasma cell neoplasm
Prostate Cancer
Skin Cancer (Non-Melanoma)
Stomach/ Gastric Cancer
Thyroid Cancer
Unknown Primary
Uterine Cancer
Trial Phase
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT02465060
Protocol IDs
EAY131 (primary)
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Study Sponsor
ECOG-ACRIN Cancer Research Group

Summary

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Objectives

PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.
II. To evaluate time until death or disease progression.
III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.
IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE:
STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes.

STEPS 1, 3, 5, 7 (Treatment): Patients are assigned to 1 of 38 treatment subprotocols based on molecularly-defined subgroup. (See Arms Section)

STEPS 2, 4, 6 (Screening): Patients experiencing disease progression on the prior Step treatment or who could not tolerate the assigned treatment undergo review of their previous biopsy results to determine if another treatment is available or undergo another biopsy. Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy.

STEP 8 (Optional Research): Consenting patients undergo end-of-treatment biopsy and collection of blood samples for research purposes.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Eligibility

  1. ELIGIBILITY CRITERIA FOR SCREENING BIOPSY (STEP 0)
  2. Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration; patients that are pregnant or breast feeding are excluded; a patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: * Has achieved menarche at some point * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  3. Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse prior to study entry, for the duration of study participation, and for 4 months after completion of study; should a patient or partner of the patient become pregnant or suspect a pregnancy while participating in this study, the treating physician should be informed immediately
  4. Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria: * Patients must have progressed following at least one line of standard systemic therapy and there must not be other approval/standard therapy available that has been shown to prolong overall survival (i.e. in a randomized trial against another standard treatment or by comparison to historical controls); patients who cannot receive other standard therapy that has been shown to prolong overall survival due to medical issues will be eligible, if other eligibility criteria are met; if the patient is currently receiving therapy, the clinician must have assessed that the current therapy is no longer benefitting the patient prior to enrolling on MATCH, regardless of whether it is considered standard OR * Patients for whose disease no standard treatment exists that has been shown to prolong overall survival * NOTE: No other prior malignancy is allowed except for the following: * Adequately treated basal cell or squamous cell skin cancer * In situ cervical cancer * Adequately treated stage I or II cancer from which the patient is currently in complete remission * Any other cancer from which the patient has been disease-free for 5 years
  5. Patients must have measurable disease
  6. Patients must meet the criteria below * Tumor tissue for the confirmation of “rare variant” by the MATCH assay is to be submitted, preferably from the same time of collection as that used to determine patient candidacy for treatment arm assignment ** Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy. There is no specific duration for which patients must be off treatment prior to registration to Step 0, as long as all eligibility criteria are met ** Patients may have received other non-targeted, immunotherapy or targeted treatment between the prior genetic testing at the outside lab and registration to Step 0. The decision to stop such treatment in favor of participation in MATCH, if no further clinical benefit is expected, is per the treating physician's discretion. Documentation of a lack of response to the prior treatment is not required in these cases ** Patients with an applicable “rare variant” must be able to meet the eligibility criteria for the appropriate subprotocols within 4 weeks following notification of treatment assignment ** Patient meets one of the following criteria: *** Patient is a candidate for Z1M based on local CLIA assessment of MMRd by immunohistochemistry (IHC) or MSI status by polymerase chain reaction (PCR), adequate tumor tissue is available for submission for mandatory central screening IHC and the patient will be able to meet the eligibility criteria for Z1M within 4 weeks following notification of treatment assignment OR *** The sites have received results from one of the designated outside laboratories indicating a “rare variant” that is an actionable Mutation of Interest (aMOI) for specific select subprotocols * NOTE: There is no particular window of time after receiving the sequencing report notification of potential eligibility from an outside lab in which the patient must be registered to Step 0, but treatment slots will be assigned on a first come, first serve basis to those who do register to Step 0, and are not held for those notified of potential eligibility who do not register to Step 0 * NOTE: Treatment assignment (and the start of the associated deadline for Step 1 registration) may occur shortly after Step 0 registration. Note that certain “rare variant” arms require submission of archival tissue for central IHC testing to determine treatment assignment. For those arms, adequate tissue for the central IHC is required to be available for submission * NOTE: Other potential aMOIs that would be eligibility criteria for “NON RARE” arms, as determined by the designated laboratories, are not applicable for this process in MATCH
  7. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 and a life expectancy of at least 3 months
  8. Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
  9. Patients who are human immunodeficiency virus (HIV)-positive are eligible if: * CD4+ cell count greater or equal to 250 cells/mm^3 * If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used * No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts * Probable long-term survival with HIV if cancer were not present
  10. Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease * NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist * NOTE: For patients entering the study via the original screening process, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the only intervening treatment permitted is prior therapy that the patient already received prior to Step 0 registration; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment * NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol
  11. Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 4 weeks prior to start of treatment
  12. Patients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted; patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7) * NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid): ** Temporary steroid use: e.g. for computed tomography (CT) imaging in setting of contrast allergy ** Low dose steroid use for appetite ** Chronic inhaled steroid use ** Steroid injections for joint disease ** Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease ** Topical steroid ** Steroids required to manage toxicity related to study treatment, as described in the subprotocols ** Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy *** NOTE: Steroids must be completed alongside last dose of chemotherapy
  13. Leukocytes >= 3,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
  14. Absolute neutrophil count (ANC) >= 1,500/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
  15. Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
  16. NOTE: Patients with documented bone marrow involvement by lymphoma are not required to meet the above hematologic parameters, but must have a platelet count of at least 75,000/mcL and neutrophil count of at least 1,000/mcL
  17. Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (unless documented Gilbert’s syndrome, for which bilirubin =< 3 x institutional ULN is permitted) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
  18. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (up to 5 times ULN in presence of liver metastases) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
  19. Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional ULN * As defined by the Cockcroft-Gault equation (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
  20. Patients must have an electrocardiogram (ECG) within 8 weeks prior to registration to screening step and must meet the following cardiac criteria: * Resting corrected QT interval (QTc) =< 480 msec ** NOTE: If the first recorded QTc exceeds 480 msec, two additional, consecutive ECGs are required and must result in a mean resting QTc =< 480 msec; it is recommended that there are 10-minute (+/- 5 minutes) breaks between the ECGs * The following only need to be assessed if the mean QTc > 480 msec ** Check potassium and magnesium serum levels ** Correct any identified hypokalemia and/or hypomagnesemia and may repeat ECG to confirm exclusion of patient due to QTc ** For patients with heart rate (HR) 60-100 beats per minute (bpm), no manual read of QTc is required ** For patients with baseline HR < 60 or > 100 bpm, manual read of QT by trained personnel is required, with Fridericia correction applied to determine QTc ** Patient must not have hypokalemia (value < institutional lower limit of normal) * No factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval ** NOTE: Patient must be taken off prohibited medication prior to registration to the screening step (Step 0, 2, 4, 6) and remain off these medications thereafter, unless permitted on a subprotocol for the management of treatment related toxicity; patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7); the medication half-life can be found in the package insert for Food and Drug Administration (FDA) approved drugs
  21. ELIGIBILITY CRITERIA FOR FIRST TREATMENT (STEP 1)
  22. NOTE: For patients entering step 0 with assay results from outside laboratories, no systemic treatment is allowed after step 0 registration
  23. As MATCH is designed to add additional subprotocols, implement limited expansions of accrual for certain subprotocols, and/or amend existing arm-specific eligibility criteria, some patients entering under the original screening method may be eligible to have their results rerun in MATCHbox, even if they did not match to a treatment initially or did not receive a treatment assignment due to a lack of available assignment slots; patients whose sequence results will be rerun through MATCHbox must also meet the following criteria: * Samples must have been collected within 5 months of the activation of the addendum, as there is an additional month needed to get the patients on trial * Patient has not had treatment within the 5 months that resulted in a PR or better after the performance of the screening assessment * Patient must meet eligibility criteria, including performance status 1 or better and life expectancy of at least 3 months * Patients must meet the eligibility requirements with the following exceptions: ** Patients may have received other non-targeted, immunotherapy or targeted treatment, which could be stopped in favor of returning to MATCH, if no response to the interim treatment has occurred and no further benefit is expected from this interim treatment, per the treating physician's discretion; documentation of a lack of response to the interim treatment is not required in these cases; however, the following restrictions apply: *** Enrollment onto another investigational therapeutic study is not permitted *** Patient cannot be responding to interim treatment, since the benefit of the MATCH treatment is unknown and may deprive patient of an effective treatment if it were given when a patient is responding to another treatment * NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 results will be re-interrogated to determine if another treatment is available
  24. ELIGIBILITY CRITERIA FOR SECOND SCREENING (STEP 2)
  25. Patient’s disease has progressed on Step 1 treatment or patient could not tolerate assigned treatment * NOTE: PATIENTS ENTERING STEP 1 WITH A “RARE VARIANT” FROM AN “OUTSIDE” LAB ARE NOT ELIGIBLE FOR STEP 2
  26. No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 1 treatment * NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance; only aMOIs detected by the MATCH assay may be used for the determination of eligibility to a relevant subprotocol OR
  27. Progression (or inability to tolerate further treatment) occurred after a (1) response OR (2) after >= 6 months from start of step 1 treatment; patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspirate for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific “actionable” mutations/amplifications of interest (aMOI); archived specimens cannot be accepted
  28. Patients must meet eligibility criteria as defined in step 0
  29. ELIGIBILITY CRITERIA FOR SECOND TREATMENT (STEP 3)
  30. NOTE: If screening biopsy samples were submitted during step 2, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 3; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 2; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply
  31. ELIGIBILITY CRITERIA FOR THIRD SCREENING (STEP 4)
  32. Patient’s disease has progressed on step 3 treatment or patient could not tolerate assigned treatment * Patient must meet one of the following criteria: ** No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 3 (second) treatment AND a biopsy was performed at step 2 screening *** NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their latest MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance OR ** Progression (or inability to tolerate further treatment) occurred on step 3 treatment and a biopsy was not performed at step 2 screening (due to presence of additional aMOIs at that stage); patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspiration for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific “actionable” mutations/amplifications of interest; biopsy must not be considered to be more than minimal risk to the patient; archived specimens cannot be accepted
  33. Patients must meet eligibility criteria as defined in step 0 * NOTE: A patient may have a maximum of 2 screening biopsies (not including re-biopsy due to assay failure), and 2 MATCH treatments per biopsy (if > 1 aMOI)
  34. ELIGIBILITY CRITERIA FOR THIRD TREATMENT (STEP 5)
  35. NOTE: If screening biopsy was submitted on step 4, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 5; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 4; the therapy cannot be an arm in the MATCH trial; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply
  36. ELIGIBILITY CRITERIA FOR FOURTH SCREENING (STEP 6)
  37. Patient’s disease has progressed on step 5 protocol treatment or patient could not tolerate assigned treatment
  38. Patient must have had no response, and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 5 treatment AND a biopsy was performed at step 4 screening *NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, based on their 2nd biopsy, their results will be interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance
  39. Patients must meet eligibility criteria as defined in step 0 * NOTE: For Step 6, biopsies to collect material for screening assay will NOT be performed; a patient may have a maximum of 2 successful screening assessments of submitted tissue (steps 0 and 2 OR steps 0 and 4), and 2 MATCH treatments per biopsy (if > 1 aMOI)
  40. ELIGIBILITY FOR FOURTH TREATMENT (STEP 7)
  41. Eligibility requirements for registration onto step 7 are outlined in the agent-specific subprotocol
  42. ELIGIBILITY CRITERIA FOR RESEARCH BIOPSY AND CIRCULATING TUMOR DNA COLLECTION (STEP 8)
  43. ALL PATIENTS SHOULD BE ENCOURAGED TO PARTICIPATE IN STEP 8, IF SAFE; IF BIOPSY IS REFUSED OR INADVISABLE, ENCOURAGE COLLECTION OF WHOLE BLOOD FOR CIRCULATING TUMOR DNA As a reminder, the submission of the step 8 samples requires additional patient consent, as well as registration to step 8 * NOTE: Patients who entered the study (step 0) with a “rare variant” determined by an outside assay ARE potentially eligible and encouraged to participate in step 8
  44. Patient has completed their most recent MATCH study treatment, will not undergo an additional screening biopsies, and will receive no additional treatment on MATCH * NOTE: If a 2nd Screening Biopsy was performed and showed no study-actionable abnormalities, and blood samples were submitted with the screening biopsy, no additional end of treatment specimens are requested
  45. For patients who consent to undergo the optional research biopsy, patient’s disease responded to the most recent MATCH study treatment and then progressed (or unable to tolerate further treatment) OR the disease progression (or inability to tolerate further treatment) occurs > 6 months since the last screening biopsy * NOTE: Performance of a biopsy to collect tumor tissue for research is strongly encouraged but not required; it is acceptable to submit only the optional blood specimens * NOTE: If a biopsy will be performed solely to collect tumor specimens for research, the patient must be willing and able to undergo a tumor biopsy or bone marrow aspirate (for applicable multiple myeloma), for the collection and submission of tissue for research

Treatment Sites in Georgia

Atlanta Cancer Care - Conyers


1498 Klondike Road
Suite 106
Conyers, GA 30094
404-303-3355
www.atlantacancercare.com

Doctors:

Richard A. Carter MD

Atlanta Cancer Care - Decatur


2545 Lawrenceville Highway
Suite 300
Decatur, GA 30033
404-303-3355
www.atlantacancercare.com

Doctors:

Lijo Simpson MD

Atlanta Cancer Care - Stockbridge


7813 Spivey Station Boulevard
Suite 210
Jonesboro, GA 30236
678 466-2069
www.atlantacancercare.com

Doctors:

Gurinderjit K. Sidhu MD
Lijo Simpson MD

Atlanta Gynecologic Oncology


980 Johnson Ferry Road
Suite 900
Atlanta, GA 30342
404-303-3355
www.geraldfeuer.com

Doctors:

Gerald A. Feuer MD

Atrium Health Navicent


Oncology Research, Atrium Health Navicent
777 Hemlock Street, MSC 123
(PACC 800 1st St, Ste 250)
Macon, GA 31201
4786332152
www.Atriumhealth.org

Study Coordinator:
Oncology Research Nurse
4786332152

Doctors:

Linda K. Hendricks MD
Bradley T. Sumrall MD
Harry F. Moore, Jr. MD

Augusta University Medical Center


1120 15th Street
Augusta, GA 30912
706-721-4430
www.augustahealth.org

Cancer Treatment Centers of America


600 Celebrate Life Parkway
Newnan, GA 30265
www.cancercenter.com

Emory Saint Joseph's Hospital


5665 Peachtree Dunwoody Road NE
Atlanta, GA 30342
www.emoryhealthcare.org

Emory University Hospital - Midtown


550 Peachtree Street NE
Atlanta, GA 30308
404-686-4411
www.emoryhealthcare.org

Georgia Cancer Specialists - CenterPointe


1100 Johnson Ferry Road
Suite 600
Sandy Springs, GA 30342
404-256-4777 ext 9242
www.gacancer.com

Doctors:

Rodolfo E. Bordoni MD
Pradeep C. Jolly MD

Georgia Cancer Specialists - Macon-Coliseum


308 Coliseum Drive
Suite 120
Macon, GA 31217
478-745-6130 x8152
www.gacancer.com

Doctors:

Cheryl F. Jones MD
Premila Malhotra MD

Harbin Clinic Cancer Center


255 West Fifth Street
Rome, GA 30165
706-528-9110
www.harbinclinic.com

Study Coordinator:
Terri Brannon
706-528-9094

Doctors:

Dilawar Khan MD

Northeast Georgia Medical Center - Gainesville


NGMC-Gainesville
Wisteria Building Suite 420
200 South Enota
Gainesville, GA 30501
770-219-8822
www.nghs.com

Study Coordinator:
Trena Davis BSN, RN, CRCC
770-219-8822

Pearlman Cancer Center at South Georgia Medical Center


2501 North Patterson Street
Valdosta, GA 31602
229-259-4628
www.sgmc.org

Piedmont Columbus Regional


1831 5th Ave
Columbus, GA 31901
www.columbusregional.com

Study Coordinator:
Jay Pitts, BS, CPhT
706-596-5426

Doctors:

Wilbur B. Bassett, Jr. MD
Andrew W. Pippas MD
Peter Q. Jiang MD
Suresh Nukala MD

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.